| CYP2C19 is one of the cytochrome P450 enzymes that are responsible for much of Phase I drug metabolism. CYP2C19 metabolizes approximately 15% all prescribed drugs including clopidogrel (Plavix), mephenytoin, diazepam, propranolol, and omeprazole. Genetic variants associated with altered CYP2C19 activities have been identified and are relatively common in most populations. Individuals with two normal activity alleles are referred to as extensive metabolizers. Individuals with two copies of the reduced /non-functional alleles (Poor Metabolizers) have decreased CYP2C19 activity, which may result in adverse drug reactions or decreased drug efficacy. Individuals with one reduced or non-functional allele and one normal activity allele may have intermediate CYP2C19 activity and are referred to as intermediate metabolizers. The anti-platelet drug clopidogrel (Plavix) is metabolized by CYP2C19 and other enzymes in the liver to an active form. Recent studies indicate that at-risk patients with reduced functional alleles who were treated with clopidogrel had a higher rate of residual platelet aggregation and cardiovascular adverse events. This analysis tests 10 different variants associated with altered CYP2C19 activity. Reasons For Referral:
Limitations:
Testing Methodology:
This analysis incorporates DNA amplification by multiplex PCR, allele specific primer extension, microarray hybridization and Fluorescence signal detection.
Analytical Sensitivity and Specificity:Greater than 99% Specimen Requirements:Blood: EDTA (purple-top) tubes: Adults: 3cc.
Turnaround Time:2 weeks CPT Codes and Prices:Index: 83891, 83900, 83901x4, 83914x20, 83912 Shipping InformationForms:References:
Test Codes:Index: 6870 |